The technologies developed by Fixed Phage are platform technologies and have the ability to address a wide range of applications in society.

This flexibility derives from the underpinning immobilisation technology, which can coat a diverse range of substrates with phages, thereby giving the base substrate inherent anti-microbial properties.

The immobilisation technology can allow us to fix phages onto substrates as diverse as plastic sheets and powders.


We work with both leading commercial partners as well as academia to deliver products that target specific bacterial issues within our core areas of industry.

Each of our partners has different capabilities that complement our own and together we design projects that have defined outcomes, whether that is creation of a new product range or pushing forward the boundaries of science.

News & Press

Athol Haas, Commercial Director at Fixed Phage

Athol Haas explains how Fixed Phage could hold the key to defeating EMS (and other aquaculture killers).

Read more >
Anti-EMS tech firm close to market launch on salmon, tilapia treatments

DUBLIN, Ireland — Biotechnology firm Fixed Phage (PG) — which works with industry partners to develop bacteria-killing products using its patented processes — is close to commercial agreements on treatments […]

Read more >
Biotech firm can combat EMS, SRS, others with phage technology

By using naturally occurring ‘phages’, company can challenge nearly any bacterial disease impacting the aquaculture industry. Biotechnology company Fixed Phage has developed a way to tackle prevalent diseases in the […]

Read more >